传统的抗体导向治疗虽然在动物体内显示出抑瘤作用,但对人体肿瘤效果不佳。其主要原因在于鼠源抗体能引起人抗鼠抗体反应,达到肿瘤内部的药量不足以及肿瘤细胞抗原异质性。以肿瘤血管而不是肿瘤细胞为靶的抗体导向治疗新策略与抗体基因工程相结合,选择小分子人抗体功能片段取代完整鼠抗体,是近年来肿瘤抗体导向治疗研究的热点之一。 Although traditional antibody-directed therapy shows anti-tumor effects in animals, it does not have a good effect on human tumors. The main reason for this is that mouse-derived antibodies can cause human anti-mouse antibody responses, resulting in insufficient intratumoral doses and heterogeneity of tumor cell antigens. The combination of antibody-directed therapeutic strategies targeting tumor vascular rather than tumor cells and antibody genetic engineering, and the selection of functional fragments of small-molecule human antibodies to replace intact murine antibodies has been one of the hot topics in tumor-directed therapy research in recent years.